 Casey Greene
Concepts (414)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Computational Biology | 32 | 2025 | 599 | 6.010 |
Why?
| | Gene Expression Profiling | 23 | 2025 | 1706 | 4.230 |
Why?
| | Software | 17 | 2025 | 608 | 3.140 |
Why?
| | Machine Learning | 18 | 2024 | 443 | 3.070 |
Why?
| | Single-Cell Analysis | 8 | 2025 | 277 | 3.060 |
Why?
| | Genomics | 18 | 2025 | 716 | 2.800 |
Why?
| | Transcriptome | 20 | 2024 | 887 | 2.660 |
Why?
| | Algorithms | 18 | 2025 | 1622 | 2.350 |
Why?
| | Gene Regulatory Networks | 10 | 2024 | 284 | 2.320 |
Why?
| | Information Dissemination | 6 | 2020 | 206 | 2.270 |
Why?
| | Epistasis, Genetic | 6 | 2023 | 70 | 1.730 |
Why?
| | Biomedical Research | 5 | 2025 | 638 | 1.670 |
Why?
| | Neoplasms | 12 | 2022 | 2470 | 1.650 |
Why?
| | Data Mining | 5 | 2018 | 110 | 1.630 |
Why?
| | Pseudomonas aeruginosa | 7 | 2024 | 347 | 1.620 |
Why?
| | Viral Vaccines | 2 | 2023 | 94 | 1.520 |
Why?
| | Sequence Analysis, RNA | 7 | 2025 | 429 | 1.490 |
Why?
| | Rare Diseases | 2 | 2023 | 100 | 1.390 |
Why?
| | Databases, Genetic | 13 | 2022 | 232 | 1.360 |
Why?
| | Ovarian Neoplasms | 7 | 2025 | 490 | 1.290 |
Why?
| | Gene Expression | 4 | 2023 | 1472 | 1.160 |
Why?
| | Research Personnel | 2 | 2020 | 156 | 1.150 |
Why?
| | Genome-Wide Association Study | 10 | 2021 | 1333 | 1.090 |
Why?
| | Humans | 102 | 2025 | 129650 | 0.990 |
Why?
| | Artificial Intelligence | 4 | 2024 | 246 | 0.980 |
Why?
| | Natural Language Processing | 2 | 2024 | 94 | 0.960 |
Why?
| | Peer Review, Research | 2 | 2022 | 41 | 0.930 |
Why?
| | Nonlinear Dynamics | 2 | 2023 | 89 | 0.920 |
Why?
| | Journalism | 1 | 2024 | 7 | 0.900 |
Why?
| | Direct-To-Consumer Screening and Testing | 1 | 2024 | 1 | 0.900 |
Why?
| | Breeding | 1 | 2024 | 62 | 0.880 |
Why?
| | Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2023 | 28 | 0.850 |
Why?
| | User-Computer Interface | 4 | 2023 | 149 | 0.770 |
Why?
| | Societies, Scientific | 1 | 2021 | 45 | 0.730 |
Why?
| | Genetic Testing | 1 | 2024 | 428 | 0.710 |
Why?
| | Neurofibromin 1 | 2 | 2019 | 25 | 0.710 |
Why?
| | Metadata | 1 | 2020 | 9 | 0.700 |
Why?
| | Data Compression | 1 | 2020 | 5 | 0.680 |
Why?
| | Guidelines as Topic | 1 | 2022 | 264 | 0.660 |
Why?
| | Computer Simulation | 7 | 2025 | 943 | 0.640 |
Why?
| | Precision Medicine | 5 | 2024 | 387 | 0.640 |
Why?
| | Computer Security | 1 | 2019 | 20 | 0.640 |
Why?
| | Genetic Association Studies | 3 | 2016 | 360 | 0.630 |
Why?
| | Language | 1 | 2022 | 283 | 0.620 |
Why?
| | Confidentiality | 1 | 2019 | 68 | 0.620 |
Why?
| | High-Throughput Nucleotide Sequencing | 4 | 2021 | 487 | 0.610 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 171 | 0.600 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2025 | 592 | 0.590 |
Why?
| | Scholarly Communication | 1 | 2018 | 2 | 0.590 |
Why?
| | Databases, Bibliographic | 1 | 2018 | 30 | 0.590 |
Why?
| | ras Proteins | 2 | 2019 | 144 | 0.580 |
Why?
| | Probability | 3 | 2024 | 306 | 0.570 |
Why?
| | Cystadenocarcinoma, Serous | 3 | 2025 | 69 | 0.570 |
Why?
| | Access to Information | 1 | 2018 | 47 | 0.570 |
Why?
| | Biomedical Technology | 1 | 2018 | 41 | 0.560 |
Why?
| | Glioblastoma | 2 | 2019 | 326 | 0.550 |
Why?
| | Disease | 3 | 2018 | 95 | 0.550 |
Why?
| | Gene Silencing | 2 | 2018 | 190 | 0.540 |
Why?
| | Models, Biological | 3 | 2020 | 1722 | 0.540 |
Why?
| | alpha-Synuclein | 1 | 2017 | 32 | 0.540 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2016 | 132 | 0.520 |
Why?
| | Parasites | 1 | 2017 | 44 | 0.520 |
Why?
| | Genome, Human | 6 | 2018 | 393 | 0.520 |
Why?
| | Systems Biology | 3 | 2018 | 59 | 0.510 |
Why?
| | Models, Genetic | 5 | 2019 | 594 | 0.510 |
Why?
| | Gene Ontology | 5 | 2020 | 51 | 0.500 |
Why?
| | Workflow | 1 | 2017 | 155 | 0.500 |
Why?
| | MicroRNAs | 1 | 2022 | 678 | 0.490 |
Why?
| | Research | 1 | 2018 | 416 | 0.480 |
Why?
| | Quantitative Trait, Heritable | 1 | 2016 | 121 | 0.480 |
Why?
| | Protein Interaction Maps | 1 | 2015 | 42 | 0.480 |
Why?
| | Neurodegenerative Diseases | 1 | 2017 | 113 | 0.480 |
Why?
| | Unsupervised Machine Learning | 4 | 2024 | 18 | 0.480 |
Why?
| | Bacterial Proteins | 2 | 2020 | 835 | 0.470 |
Why?
| | Internet | 5 | 2023 | 617 | 0.450 |
Why?
| | Tumor Microenvironment | 4 | 2023 | 634 | 0.440 |
Why?
| | Authorship | 2 | 2024 | 45 | 0.440 |
Why?
| | Models, Theoretical | 1 | 2017 | 547 | 0.430 |
Why?
| | Bayes Theorem | 5 | 2018 | 375 | 0.420 |
Why?
| | RNA, Untranslated | 1 | 2014 | 117 | 0.390 |
Why?
| | Cluster Analysis | 3 | 2024 | 482 | 0.370 |
Why?
| | Pandemics | 5 | 2023 | 1488 | 0.370 |
Why?
| | Drosophila melanogaster | 5 | 2019 | 215 | 0.370 |
Why?
| | Microbiota | 2 | 2017 | 730 | 0.370 |
Why?
| | Signal Transduction | 8 | 2020 | 4925 | 0.360 |
Why?
| | Bibliometrics | 2 | 2024 | 54 | 0.360 |
Why?
| | Writing | 2 | 2024 | 91 | 0.350 |
Why?
| | Publishing | 2 | 2024 | 140 | 0.340 |
Why?
| | Databases, Factual | 2 | 2018 | 1269 | 0.340 |
Why?
| | Embryonic Development | 3 | 2020 | 114 | 0.330 |
Why?
| | Terminology as Topic | 3 | 2022 | 204 | 0.320 |
Why?
| | Molecular Sequence Annotation | 5 | 2023 | 87 | 0.320 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2010 | 68 | 0.320 |
Why?
| | Scleroderma, Systemic | 3 | 2017 | 114 | 0.310 |
Why?
| | Genome | 2 | 2019 | 278 | 0.300 |
Why?
| | Supervised Machine Learning | 2 | 2020 | 17 | 0.300 |
Why?
| | Female | 22 | 2025 | 68776 | 0.300 |
Why?
| | Betacoronavirus | 2 | 2020 | 249 | 0.280 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2021 | 2073 | 0.280 |
Why?
| | Animals | 19 | 2025 | 35361 | 0.280 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 814 | 0.270 |
Why?
| | Drosophila Proteins | 2 | 2019 | 186 | 0.260 |
Why?
| | Proteomics | 4 | 2021 | 1062 | 0.250 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 341 | 0.240 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2021 | 270 | 0.240 |
Why?
| | Coronavirus Infections | 2 | 2020 | 335 | 0.240 |
Why?
| | Data Interpretation, Statistical | 2 | 2018 | 335 | 0.240 |
Why?
| | Publications | 2 | 2022 | 41 | 0.230 |
Why?
| | Reproducibility of Results | 6 | 2021 | 3083 | 0.230 |
Why?
| | Genetic Predisposition to Disease | 5 | 2021 | 2282 | 0.220 |
Why?
| | Mice | 12 | 2025 | 16937 | 0.220 |
Why?
| | Cystic Fibrosis | 2 | 2024 | 1053 | 0.210 |
Why?
| | Sexism | 1 | 2024 | 55 | 0.210 |
Why?
| | Science | 1 | 2024 | 49 | 0.210 |
Why?
| | Breast Neoplasms | 2 | 2015 | 2142 | 0.210 |
Why?
| | Cell Line, Tumor | 4 | 2019 | 3215 | 0.210 |
Why?
| | Causality | 1 | 2023 | 117 | 0.210 |
Why?
| | Dogs | 1 | 2024 | 381 | 0.200 |
Why?
| | Pedigree | 1 | 2024 | 487 | 0.200 |
Why?
| | Vaccines, Subunit | 1 | 2023 | 48 | 0.200 |
Why?
| | Male | 16 | 2025 | 63681 | 0.200 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2019 | 228 | 0.200 |
Why?
| | Sample Size | 1 | 2022 | 116 | 0.200 |
Why?
| | Mushroom Bodies | 2 | 2019 | 3 | 0.190 |
Why?
| | Hedgehog Proteins | 2 | 2021 | 188 | 0.190 |
Why?
| | Pseudomonas Infections | 1 | 2024 | 221 | 0.190 |
Why?
| | Periodicals as Topic | 1 | 2024 | 204 | 0.180 |
Why?
| | High-Throughput Screening Assays | 2 | 2014 | 138 | 0.180 |
Why?
| | Quality Control | 1 | 2021 | 163 | 0.180 |
Why?
| | Neoplasm Grading | 4 | 2025 | 285 | 0.180 |
Why?
| | Electronic Health Records | 3 | 2018 | 975 | 0.180 |
Why?
| | ADAM10 Protein | 1 | 2021 | 30 | 0.180 |
Why?
| | Cooperative Behavior | 2 | 2021 | 433 | 0.180 |
Why?
| | Pancreatic Neoplasms | 2 | 2021 | 882 | 0.180 |
Why?
| | Bone Development | 1 | 2021 | 49 | 0.180 |
Why?
| | Gamma Rays | 1 | 2021 | 54 | 0.170 |
Why?
| | Fibrosis | 2 | 2021 | 520 | 0.170 |
Why?
| | Linear Models | 1 | 2023 | 819 | 0.170 |
Why?
| | Alzheimer Disease | 2 | 2017 | 519 | 0.170 |
Why?
| | Mutation | 5 | 2025 | 3717 | 0.170 |
Why?
| | Cystadenoma, Serous | 1 | 2020 | 18 | 0.170 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 80 | 0.170 |
Why?
| | Medical Informatics | 1 | 2021 | 99 | 0.170 |
Why?
| | Organ Specificity | 3 | 2017 | 296 | 0.170 |
Why?
| | Privacy | 1 | 2020 | 32 | 0.170 |
Why?
| | Bone Diseases | 1 | 2021 | 57 | 0.170 |
Why?
| | Hemerythrin | 1 | 2020 | 1 | 0.170 |
Why?
| | Histone Code | 1 | 2020 | 31 | 0.170 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2020 | 1356 | 0.160 |
Why?
| | Radiation Injuries | 1 | 2021 | 135 | 0.160 |
Why?
| | Systems Integration | 2 | 2017 | 38 | 0.160 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 94 | 0.160 |
Why?
| | Neurofibromatosis 1 | 1 | 2020 | 47 | 0.160 |
Why?
| | Radiosurgery | 1 | 2022 | 321 | 0.160 |
Why?
| | Phenotype | 4 | 2021 | 3076 | 0.160 |
Why?
| | Genetic Fitness | 1 | 2020 | 54 | 0.160 |
Why?
| | Cerebellar Neoplasms | 1 | 2021 | 156 | 0.160 |
Why?
| | Papillomavirus Infections | 1 | 2022 | 297 | 0.160 |
Why?
| | Biofilms | 2 | 2019 | 244 | 0.160 |
Why?
| | Base Sequence | 1 | 2022 | 2142 | 0.150 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 202 | 0.150 |
Why?
| | Exons | 1 | 2020 | 342 | 0.150 |
Why?
| | DNA Repair | 2 | 2011 | 207 | 0.150 |
Why?
| | Cell Hypoxia | 1 | 2020 | 235 | 0.150 |
Why?
| | Medulloblastoma | 1 | 2021 | 198 | 0.150 |
Why?
| | Computer Communication Networks | 1 | 2018 | 32 | 0.150 |
Why?
| | Gene Expression Regulation | 3 | 2018 | 2548 | 0.150 |
Why?
| | Proteins | 2 | 2016 | 942 | 0.150 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2019 | 511 | 0.150 |
Why?
| | Pseudomonas fluorescens | 1 | 2018 | 3 | 0.150 |
Why?
| | Biomarkers, Tumor | 1 | 2025 | 1181 | 0.150 |
Why?
| | Sex Factors | 1 | 2024 | 1968 | 0.150 |
Why?
| | Hypertension | 2 | 2019 | 1242 | 0.150 |
Why?
| | Down Syndrome | 1 | 2025 | 481 | 0.150 |
Why?
| | Alternative Splicing | 1 | 2020 | 218 | 0.150 |
Why?
| | Recombinational DNA Repair | 1 | 2018 | 13 | 0.150 |
Why?
| | Atlases as Topic | 1 | 2018 | 10 | 0.150 |
Why?
| | Multiple Myeloma | 1 | 2019 | 125 | 0.150 |
Why?
| | Cyclic GMP | 1 | 2018 | 90 | 0.140 |
Why?
| | Pennsylvania | 1 | 2018 | 108 | 0.140 |
Why?
| | Bone and Bones | 1 | 2021 | 299 | 0.140 |
Why?
| | Immunity, Cellular | 1 | 2019 | 265 | 0.140 |
Why?
| | Glomerulonephritis | 1 | 2018 | 46 | 0.140 |
Why?
| | False Positive Reactions | 1 | 2018 | 114 | 0.140 |
Why?
| | Public Sector | 1 | 2017 | 17 | 0.140 |
Why?
| | Central Nervous System Neoplasms | 1 | 2019 | 149 | 0.140 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 544 | 0.140 |
Why?
| | Starvation | 1 | 2017 | 22 | 0.140 |
Why?
| | Phosphoproteins | 1 | 2019 | 332 | 0.140 |
Why?
| | Trans-Activators | 1 | 2020 | 388 | 0.140 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 641 | 0.140 |
Why?
| | Drug Design | 1 | 2018 | 156 | 0.140 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 424 | 0.140 |
Why?
| | Metabolic Networks and Pathways | 1 | 2018 | 178 | 0.140 |
Why?
| | Information Storage and Retrieval | 1 | 2017 | 108 | 0.130 |
Why?
| | Body Mass Index | 1 | 2025 | 2273 | 0.130 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 278 | 0.130 |
Why?
| | Data Collection | 1 | 2019 | 650 | 0.130 |
Why?
| | Genome, Microbial | 1 | 2016 | 7 | 0.130 |
Why?
| | Amygdala | 1 | 2017 | 198 | 0.130 |
Why?
| | Phylogeny | 1 | 2020 | 852 | 0.130 |
Why?
| | Microbial Consortia | 1 | 2016 | 19 | 0.120 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2015 | 18 | 0.120 |
Why?
| | Drug Repositioning | 1 | 2015 | 25 | 0.120 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2018 | 769 | 0.120 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2018 | 324 | 0.120 |
Why?
| | Memory | 1 | 2017 | 255 | 0.120 |
Why?
| | Antihypertensive Agents | 1 | 2019 | 485 | 0.120 |
Why?
| | Research Design | 1 | 2021 | 1044 | 0.120 |
Why?
| | Structure-Activity Relationship | 1 | 2016 | 548 | 0.120 |
Why?
| | Toxicology | 1 | 2015 | 41 | 0.120 |
Why?
| | Blood Pressure | 2 | 2019 | 1736 | 0.120 |
Why?
| | Search Engine | 1 | 2015 | 10 | 0.120 |
Why?
| | Social Behavior | 1 | 2017 | 289 | 0.120 |
Why?
| | Knowledge Bases | 1 | 2015 | 24 | 0.120 |
Why?
| | RNA | 4 | 2024 | 883 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2021 | 1119 | 0.110 |
Why?
| | Metabolome | 1 | 2017 | 338 | 0.110 |
Why?
| | Prognosis | 3 | 2021 | 3794 | 0.110 |
Why?
| | Decision Support Techniques | 1 | 2018 | 396 | 0.110 |
Why?
| | Circadian Rhythm | 1 | 2017 | 413 | 0.110 |
Why?
| | Pharmacogenetics | 1 | 2015 | 175 | 0.110 |
Why?
| | Genes | 3 | 2013 | 226 | 0.110 |
Why?
| | Hospital Mortality | 1 | 2018 | 850 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1368 | 0.110 |
Why?
| | Biological Phenomena | 1 | 2013 | 4 | 0.110 |
Why?
| | Macrophages | 1 | 2021 | 1480 | 0.100 |
Why?
| | Proteome | 1 | 2017 | 443 | 0.100 |
Why?
| | Intensive Care Units | 1 | 2018 | 738 | 0.100 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2015 | 259 | 0.100 |
Why?
| | Sequence Analysis, DNA | 3 | 2025 | 779 | 0.100 |
Why?
| | Podocytes | 1 | 2013 | 52 | 0.100 |
Why?
| | Length of Stay | 1 | 2018 | 1127 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2017 | 1838 | 0.100 |
Why?
| | Brain | 1 | 2024 | 2679 | 0.100 |
Why?
| | Receptors, Estrogen | 1 | 2015 | 426 | 0.100 |
Why?
| | Cell Lineage | 1 | 2013 | 333 | 0.090 |
Why?
| | Survival Analysis | 1 | 2015 | 1274 | 0.090 |
Why?
| | Obesity | 1 | 2025 | 2883 | 0.090 |
Why?
| | Polymorphism, Genetic | 2 | 2017 | 640 | 0.090 |
Why?
| | Cell Line | 2 | 2017 | 2781 | 0.090 |
Why?
| | Pediatrics | 1 | 2019 | 1052 | 0.090 |
Why?
| | Decision Making | 1 | 2018 | 851 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2018 | 894 | 0.090 |
Why?
| | Bias | 1 | 2012 | 196 | 0.090 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1171 | 0.090 |
Why?
| | Microglia | 2 | 2024 | 235 | 0.090 |
Why?
| | Knowledge | 1 | 2010 | 51 | 0.080 |
Why?
| | Multifactor Dimensionality Reduction | 1 | 2010 | 2 | 0.080 |
Why?
| | Models, Statistical | 3 | 2020 | 623 | 0.080 |
Why?
| | Memory, Long-Term | 2 | 2019 | 13 | 0.080 |
Why?
| | Transcription Factors | 1 | 2017 | 1651 | 0.080 |
Why?
| | Kidney Diseases | 1 | 2013 | 384 | 0.080 |
Why?
| | Parkinson Disease | 1 | 2015 | 463 | 0.080 |
Why?
| | Aged | 7 | 2025 | 22103 | 0.080 |
Why?
| | Rats | 3 | 2013 | 5500 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1279 | 0.080 |
Why?
| | Geography | 1 | 2009 | 188 | 0.080 |
Why?
| | Child | 4 | 2021 | 20883 | 0.080 |
Why?
| | Adult | 6 | 2025 | 35576 | 0.080 |
Why?
| | Biopsy | 3 | 2018 | 1097 | 0.070 |
Why?
| | Gene Frequency | 1 | 2009 | 503 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 5406 | 0.070 |
Why?
| | Middle Aged | 8 | 2025 | 31154 | 0.070 |
Why?
| | Cells, Cultured | 1 | 2015 | 4083 | 0.070 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2013 | 566 | 0.070 |
Why?
| | United States | 2 | 2021 | 13903 | 0.070 |
Why?
| | Multifactorial Inheritance | 1 | 2008 | 150 | 0.070 |
Why?
| | Alleles | 1 | 2009 | 845 | 0.060 |
Why?
| | Terminal Repeat Sequences | 1 | 2006 | 15 | 0.060 |
Why?
| | Cytokines | 2 | 2018 | 2017 | 0.060 |
Why?
| | Retroelements | 1 | 2006 | 44 | 0.060 |
Why?
| | Bone Density | 2 | 2021 | 471 | 0.060 |
Why?
| | Treatment Outcome | 1 | 2019 | 10230 | 0.060 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2025 | 40 | 0.060 |
Why?
| | Pilot Projects | 2 | 2022 | 1587 | 0.060 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2025 | 43 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2009 | 3381 | 0.060 |
Why?
| | Europe | 1 | 2025 | 364 | 0.050 |
Why?
| | Culture Media | 1 | 2024 | 162 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2024 | 98 | 0.050 |
Why?
| | Metals | 1 | 2024 | 128 | 0.050 |
Why?
| | Microarray Analysis | 1 | 2023 | 122 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2025 | 525 | 0.050 |
Why?
| | Astrocytes | 1 | 2024 | 201 | 0.050 |
Why?
| | Smoking | 1 | 2010 | 1501 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 5440 | 0.050 |
Why?
| | Sputum | 1 | 2024 | 302 | 0.050 |
Why?
| | Budgets | 1 | 2021 | 12 | 0.050 |
Why?
| | Interdisciplinary Research | 1 | 2021 | 26 | 0.050 |
Why?
| | Gene Library | 1 | 2021 | 116 | 0.050 |
Why?
| | Ephrin-B2 | 1 | 2021 | 50 | 0.040 |
Why?
| | Neurofibroma | 1 | 2020 | 3 | 0.040 |
Why?
| | Nerve Sheath Neoplasms | 1 | 2020 | 10 | 0.040 |
Why?
| | Gene Editing | 1 | 2021 | 68 | 0.040 |
Why?
| | Neurofibroma, Plexiform | 1 | 2020 | 9 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2025 | 7086 | 0.040 |
Why?
| | DNA, Mitochondrial | 1 | 2021 | 191 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2022 | 383 | 0.040 |
Why?
| | Genetic Markers | 1 | 2021 | 338 | 0.040 |
Why?
| | Osteoblasts | 1 | 2021 | 124 | 0.040 |
Why?
| | Antigens, CD20 | 1 | 2019 | 27 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2020 | 84 | 0.040 |
Why?
| | Data Accuracy | 1 | 2020 | 57 | 0.040 |
Why?
| | Candida albicans | 1 | 2019 | 53 | 0.040 |
Why?
| | Chromosome Mapping | 1 | 2021 | 504 | 0.040 |
Why?
| | Young Adult | 3 | 2021 | 12426 | 0.040 |
Why?
| | Manuscripts, Medical as Topic | 1 | 2019 | 5 | 0.040 |
Why?
| | Peripheral Nerves | 1 | 2020 | 69 | 0.040 |
Why?
| | Genome, Fungal | 1 | 2019 | 33 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2020 | 120 | 0.040 |
Why?
| | Reward | 1 | 2021 | 240 | 0.040 |
Why?
| | Osteogenesis | 1 | 2021 | 175 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 940 | 0.040 |
Why?
| | Osteosarcoma | 1 | 2019 | 72 | 0.040 |
Why?
| | Rhabdomyosarcoma | 1 | 2019 | 64 | 0.040 |
Why?
| | Mentoring | 1 | 2021 | 131 | 0.040 |
Why?
| | Locomotion | 1 | 2019 | 100 | 0.040 |
Why?
| | Genome, Bacterial | 1 | 2019 | 134 | 0.040 |
Why?
| | Quantitative Trait Loci | 1 | 2021 | 355 | 0.040 |
Why?
| | Wilms Tumor | 1 | 2019 | 77 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2019 | 315 | 0.040 |
Why?
| | Neuroblastoma | 1 | 2019 | 154 | 0.040 |
Why?
| | Genes, Neoplasm | 1 | 2018 | 20 | 0.040 |
Why?
| | Sarcoma, Ewing | 1 | 2019 | 89 | 0.040 |
Why?
| | Bacteria | 1 | 2025 | 821 | 0.040 |
Why?
| | Two-Hybrid System Techniques | 1 | 2018 | 56 | 0.040 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 211 | 0.040 |
Why?
| | Loss of Heterozygosity | 1 | 2018 | 46 | 0.040 |
Why?
| | Pentose Phosphate Pathway | 1 | 2018 | 50 | 0.040 |
Why?
| | Nephrotic Syndrome | 1 | 2018 | 28 | 0.040 |
Why?
| | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2018 | 23 | 0.040 |
Why?
| | Monocytes | 1 | 2021 | 551 | 0.040 |
Why?
| | Mobile Applications | 1 | 2020 | 160 | 0.040 |
Why?
| | Acid Phosphatase | 1 | 2017 | 20 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2019 | 312 | 0.040 |
Why?
| | Kidney Glomerulus | 1 | 2018 | 109 | 0.040 |
Why?
| | Mouth | 1 | 2017 | 84 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2020 | 455 | 0.030 |
Why?
| | Kidney Tubules | 1 | 2018 | 114 | 0.030 |
Why?
| | RNA-Binding Proteins | 1 | 2021 | 388 | 0.030 |
Why?
| | Patient Care Planning | 1 | 2018 | 149 | 0.030 |
Why?
| | Isoenzymes | 1 | 2018 | 302 | 0.030 |
Why?
| | GTPase-Activating Proteins | 1 | 2017 | 81 | 0.030 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2017 | 87 | 0.030 |
Why?
| | Wnt Proteins | 1 | 2018 | 127 | 0.030 |
Why?
| | Chromatin | 1 | 2021 | 479 | 0.030 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2017 | 85 | 0.030 |
Why?
| | Motivation | 1 | 2021 | 546 | 0.030 |
Why?
| | Databases, Protein | 1 | 2016 | 62 | 0.030 |
Why?
| | Recurrence | 1 | 2019 | 1007 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 1877 | 0.030 |
Why?
| | Cell Movement | 1 | 2021 | 945 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2021 | 1207 | 0.030 |
Why?
| | Saliva | 1 | 2017 | 209 | 0.030 |
Why?
| | Proof of Concept Study | 1 | 2016 | 69 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2021 | 663 | 0.030 |
Why?
| | Biopsy, Fine-Needle | 1 | 2016 | 68 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2018 | 359 | 0.030 |
Why?
| | Genetic Loci | 1 | 2017 | 275 | 0.030 |
Why?
| | Blood Proteins | 1 | 2017 | 242 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2018 | 317 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2019 | 716 | 0.030 |
Why?
| | DNA Damage | 1 | 2018 | 384 | 0.030 |
Why?
| | Hydrocortisone | 1 | 2017 | 307 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2018 | 457 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2018 | 247 | 0.030 |
Why?
| | Health Status | 1 | 2020 | 755 | 0.030 |
Why?
| | Risk Factors | 1 | 2009 | 9765 | 0.030 |
Why?
| | Oxygen | 1 | 2020 | 915 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 1988 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2021 | 857 | 0.030 |
Why?
| | Esophagus | 1 | 2017 | 248 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1004 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2021 | 1418 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2016 | 588 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2017 | 545 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2019 | 821 | 0.030 |
Why?
| | Aging | 1 | 2024 | 1776 | 0.030 |
Why?
| | Colorado | 1 | 2024 | 4421 | 0.030 |
Why?
| | Heart Rate | 1 | 2017 | 802 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 891 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 610 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2021 | 2391 | 0.030 |
Why?
| | Regression Analysis | 1 | 2015 | 993 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2717 | 0.030 |
Why?
| | Support Vector Machine | 1 | 2013 | 37 | 0.030 |
Why?
| | Organogenesis | 1 | 2013 | 56 | 0.030 |
Why?
| | Embryo, Nonmammalian | 1 | 2013 | 166 | 0.020 |
Why?
| | Nanotechnology | 1 | 2013 | 122 | 0.020 |
Why?
| | Computer Graphics | 1 | 2012 | 41 | 0.020 |
Why?
| | Risk | 1 | 2015 | 854 | 0.020 |
Why?
| | Skin | 1 | 2017 | 725 | 0.020 |
Why?
| | Adolescent | 2 | 2021 | 20393 | 0.020 |
Why?
| | Apoptosis | 1 | 2021 | 2503 | 0.020 |
Why?
| | Drug Interactions | 1 | 2013 | 394 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 2015 | 504 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2018 | 2708 | 0.020 |
Why?
| | Genetic Variation | 1 | 2015 | 937 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5066 | 0.020 |
Why?
| | Caenorhabditis elegans | 1 | 2013 | 291 | 0.020 |
Why?
| | Zebrafish Proteins | 1 | 2012 | 265 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4063 | 0.020 |
Why?
| | Repressor Proteins | 1 | 2012 | 406 | 0.020 |
Why?
| | Zebrafish | 1 | 2013 | 458 | 0.020 |
Why?
| | Curriculum | 1 | 2015 | 917 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 1016 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 6556 | 0.020 |
Why?
| | Child, Preschool | 1 | 2021 | 10517 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2013 | 1902 | 0.020 |
Why?
| | Lung | 1 | 2017 | 3930 | 0.010 |
Why?
| | Inflammation | 1 | 2015 | 2736 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2344 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2018 | 14518 | 0.010 |
Why?
|
|
Greene's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|